Assets
(39 total)
39Total Assets
14Approved
10Phase 3 / Filed
15Phase 1–2 / Early
20Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisRheumatoid Arthritis Ulcerative Colitis, Crohn's Disease | |
Afatinib(Gilotrif) | Approved | EGFR/HER1, HER2, HER4Small molecule | Non-Small Cell Lung Cancer |
Empagliflozin(Jardiance) | Approved | SGLT2Small molecule | Type 2 DiabetesHeart FailureChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease |
Linagliptin(Tradjenta) | Approved | DPP-4Small molecule | Type 2 Diabetes |
| Approved | PDE4B | Idiopathic Pulmonary Fibrosis | |
| Approved | Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR)Small molecule | Non-Small Cell Lung CancerIdiopathic Pulmonary Fibrosis | |
| Approved | Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary DiseaseAsthma | |
| Approved | Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptorSmall molecule | Chronic Obstructive Pulmonary DiseaseAsthma | |
Pramipexole(Sifrol/Mirapex) | Approved | Dopamine D2/D3 receptorsSmall molecule | Parkinson's Disease |
| Approved | Dopamine D2 / D3 receptorsSmall molecule | Parkinson's Disease | |
spesolimab(Spevigo (approved elsewhere, for GPP)) | Approved | IL-36 receptorMonoclonal antibody | Psoriasis |
| Approved | Muscarinic acetylcholine receptor (M3)Small molecule | Chronic Obstructive Pulmonary DiseaseAsthma | |
Tipranavir(Aptivus) | Approved | HIV proteaseSmall molecule | HIV |
| Approved | HER2 · HER2 Mutant-selectiveSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | TRPC6 (transient receptor potential cation channel subfamily C member 6)Small molecule | Chronic Kidney Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.